Poxel

Website

Advertisement

1 Broadway Ste 14
Cambridge, MA 02142

Poxel is a clinical-stage biopharmaceutical company based in Cambridge, MA, specializing in the development of innovative treatments for chronic serious diseases with metabolic pathophysiology, particularly focusing on non-alcoholic steatohepatitis (NASH) and rare disorders. The company boasts a robust pipeline, including mid-stage products PXL065 and PXL770, as well as the approved product TWYMEEG (Imeglimin), which is marketed for the treatment of type 2 diabetes in Japan.

With a commitment to targeting mitochondrial dysfunction, Poxel aims to offer safer and more effective therapies through its disease-modifying mechanisms of action. The company is supported by a highly experienced clinical and regulatory team, enhancing its capability to successfully develop and commercialize its products.

Generated from the website

Own this business?
See a problem?

You might also like

Partial Data by Infogroup (c) 2025. All rights reserved.

Advertisement